Navigation Links
Mindray Announces 2008 Fourth Quarter and Full Year Results
Date:3/4/2009

(24) (35) Operating income 22,264 31,653 80,013 117,519 Other income, net 833 2,008 2,357 4,918 Interest income 2,718 875 9,726 8,361 Interest expense (3) (2,626) (11) (5,163) Income before income taxes and minority interests 25,812 31,910 92,085 125,635 Provision for income taxes (4,350) (308) (14,043) (16,948) Minority interests -- -- -- -- Net Income 21,462 31,602 78,042 108,687 Basic earnings per share 0.20 0.29 0.73 1.01 Diluted earnings per share 0.19 0.28 0.69 0.96 Shares used in the computation of: Basic earnings per share 106,774,444 107,689,743 106,328,347 107,366,250 Diluted earnings per share 113,457,341 112,316,513 112,678,984 113,364,756 (4) Share-based compensation charges incurred during the period related to: Cost of revenues 112 89 267 423 Selling expenses 817 356 2,781 2,870 General and administrative expenses 577 700 2,232 2,697 Research and development expenses 862 414 2,431 2,731 (5) Amortization of intangible assets increased $1.6 million during the three-month period ended September 30, 2008 as a result of recognizing the cumulative effect of an understatement of amortization of intangible assets during the year ended December 31, 2006
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Mindray Medical International Announces Second Quarter 2008 Results
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. Mindray Medical International Announces First Quarter 2008 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. Mindray Medical International Announces Third Quarter 2007 Results
6. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Martek Announces First Quarter 2009 Financial Results
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2010)... is taking strides to expand their Product and Material Testing Division ... ... Minneapolis, MN (PRWEB) March 12, 2010 -- DDL , leader ... to expand their Product and Material Testing Division by promoting Mark ... medical device manufacturers get to market for almost 20 years. ...
(Date:3/11/2010)... Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone ... ... , ... ... ...
(Date:3/11/2010)... has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide ... ... ... ... ...
(Date:3/11/2010)... a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered ... for Sick Children (SickKids) in Toronto, Ontario , granting Trillium exclusive worldwide ... transplantation and cancer. , ... ... , ...
Breaking Biology Technology:DDL Expands the Product & Material Testing Division 2DDL Expands the Product & Material Testing Division 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3
... 7, 2008 Light Sciences Oncology,Inc. (LSO) today announced ... Directors. The appointment increases Board membership to eight., ... a Director,of Endo Pharmaceuticals. He is the former President ... of Corporate Development with,Johnson & Johnson (NYSE: JNJ ...
... payments for achieving milestones ... ... TSX symbol: SBS, CALGARY, April 7 /PRNewswire-FirstCall/ - SemBioSys Genetics ... and cardiovascular diseases, today announced that it,has received milestone payments totaling ...
... Dr. David S. Young awarded "Most Innovative" award by the ... ... - ARIUS Research Inc. (TSX:,ARI), a biotechnology company discovering and ... David S. Young, President,and Chief Executive Officer, received the "Most ...
Other Biology Technology:Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors 2SemBioSys receives milestone payments from AVAC Ltd. 2SemBioSys receives milestone payments from AVAC Ltd. 3SemBioSys receives milestone payments from AVAC Ltd. 4ARIUS recognized for entrepreneurial excellence 2
(Date:3/11/2010)... wisdom holds that living cells interact with their ... a result many therapies for the treatment of cancer ... focus on drugs that block or disrupt harmful chemical ... have been opened with scientific evidence for a never ... and respond to physical forces. , A team of ...
(Date:3/11/2010)... a chunk of rock and dust about 1,900 feet in ... born, and perhaps, shed light on how life began. It ... time capsule from before the birth of our solar system," ... Greenbelt, Md., one of the leaders of Goddard,s effort to ... from RQ36. , If selected, Goddard will provide overall ...
(Date:3/11/2010)... the body, they follow a complex pattern similar ... searching for food, a team of Vanderbilt researchers ... for drug development: Incorporating this basic behavior into ... migration, such as embryo development, bone remodeling, wound ... accuracy with which these models can predict the ...
Breaking Biology News(10 mins):Berkeley scientists find new way to get physical in the fight against cancer 2Berkeley scientists find new way to get physical in the fight against cancer 3Berkeley scientists find new way to get physical in the fight against cancer 4Proposed mission would return sample from asteroid 'time capsule' 2Proposed mission would return sample from asteroid 'time capsule' 3Proposed mission would return sample from asteroid 'time capsule' 4Proposed mission would return sample from asteroid 'time capsule' 5Human cells exhibit foraging behavior like amoebae and bacteria 2Human cells exhibit foraging behavior like amoebae and bacteria 3Big Whoppers of 2009 from FactCheck org 63927 1Big Whoppers of 2009 from FactCheck org 63927 2National Disability Lawyer Gets 2010 Social Security Website Upgrade 63924 1National Disability Lawyer Gets 2010 Social Security Website Upgrade 63924 2Dont Invite Holiday Stress Into Your Home 63920 1Dont Invite Holiday Stress Into Your Home 63920 2
... One of the simplest plants on the planet could help ... The moss Physcomitrella patens is a primitive plant, similar to ... 450 million years ago. Just one cell thick, these early ... without roots or complex leaves. The ability of mosses to ...
... a paper today that is the most comprehensive review ... having on the worlds coral reefs. The Carbon ... Ocean Acidification, co-authored by seventeen marine scientists from seven ... survive the drastic increases in global temperatures and atmospheric ...
... funded by the Lupus Research Institute (LRI) has discovered ... the inflammatory response of the immune system. The major ... journal Cell, means that new methods can now be ... regulation, and treat chronic autoimmune disorders such as lupus. ...
Other Biology News:Moss is a super model for feeding the hungry 2Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Profound immune system discovery opens door to halting destruction of lupus 2Profound immune system discovery opens door to halting destruction of lupus 3